Provided by Tiger Fintech (Singapore) Pte. Ltd.

Karyopharm Therapeutics

4.39
-0.2200-4.77%
Post-market: 4.600.2100+4.78%16:28 EDT
Volume:36.02K
Turnover:164.32K
Market Cap:37.93M
PE:-0.35
High:4.83
Open:4.69
Low:4.39
Close:4.61
Loading ...

Karyopharm Therapeutics Inc expected to post a loss of $4.18 a share - Earnings Preview

Reuters
·
10 May

Karyopharm Therapeutics Inc expected to post a loss of $4.18 a share - Earnings Preview

Reuters
·
02 May

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
02 May

RBC Lowers Price Target on Karyopharm Therapeutics to $43 From $45, Keeps Outperform Rating

MT Newswires Live
·
03 Apr

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
02 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

Karyopharm Therapeutics (KPTI) Receives a Buy from Piper Sandler

TIPRANKS
·
19 Mar

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
04 Mar

Karyopharm Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
03 Mar

Karyopharm Therapeutics Inc : Baird Cuts Target Price to $54 From $75

THOMSON REUTERS
·
28 Feb

Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
26 Feb

Karyopharm Therapeutics Inc : H.c. Wainwright Adjusts Target Price to $56 From $7 to Reflect 1-for-15 Reverse Stock Split

THOMSON REUTERS
·
26 Feb

Karyopharm trading halted, news pending

TIPRANKS
·
26 Feb

Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split

MT Newswires Live
·
25 Feb

Karyopharm Announces 1-for-15 Reverse Stock Split

THOMSON REUTERS
·
24 Feb

Karyopharm Announces 1-for-15 Reverse Stock Split

PR Newswire
·
24 Feb

Karyopharm Therapeutics: Hold Rating Maintained Amid Revenue Stagnation and Competitive Pressures

TIPRANKS
·
23 Feb

Karyopharm Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Feb

Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating

TIPRANKS
·
20 Feb

Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
20 Feb